Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
14/05/2026 13:51
May 14 (Reuters) - Senti Biosciences Holdings Inc SNTI.O: SENTI BIOSCIENCES HOLDINGS ANNOUNCES POSITIVE FDA RMAT MEETING ON REGISTRATIONAL CLINICAL AND CMC STRATEGY FOR SENTI-202 IN RELAPSED/REFRACTORY AML, ALONG WITH IMPORTANT EFFICACY AND DURABILITY UPDATES ON THE SENTI-202 CLINICAL PROGRAM SENTI BIOSCIENCES HOLDINGS INC - TO INITIATE SINGLE-ARM MULTI-CENTER REGISTRATION TRIAL FOR SENTI-202 IN R/R AML SENTI BIOSCIENCES HOLDINGS INC - SENTI-202 FUTURE MANUFACTURING TO USE DONOR X PHENOTYPE Source text: ID:nGNX36HSqF Further company coverage: SNTI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Senti Biosciences Holdings
See all newsBrief: Senti Biosciences Says Offering 15.97 Million Shares Of Common Stock For Resale By Selling Securityholder
Senti Biosciences Q1 net loss narrows on cost reduction
Brief: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy
Brief: Senti Biosciences Announces Holding Company Reorganization Effective By April 16, 2026 - SEC Filing
Senti Biosciences Q4 revenue misses analyst estimates